BioCardia Inc logo

BCDA - BioCardia Inc News Story

$3.47 0.0  0.6%

Last Trade - 05/05/21

Sector
Healthcare
Size
Micro Cap
Market Cap £41.7m
Enterprise Value £26.3m
Revenue £104k
Position in Universe 5547th / 6846

BioCardia to Present at Maxim Group’s Inaugural Emerging Growth Virtual Conference

Mon 15th March, 2021 12:00pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210315:nGNXbDpQhs&default-theme=true


SAN CARLOS, Calif., March 15, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc.
(https://www.globenewswire.com/Tracker?data=Tbg1FkE2HlbyGeidwuDDrqIEYaeXAcgD5d9qBdT6IIqvopoFW48-KvjMBM-7CJzoIaFviZZz8rZQvFQZucCRuICRTnSu8cQon-1msxWlWSO2-iT1O1NRw2kg_uyZqm-tyg5sbNV_J6l9vUnoI_kU-0NcfLHlSIdFttBY2rKkTVFYWeD825Hh1B-8O2yh-uV6__MaTkuLXh5ZmxZ4BSA8dCjhlkCpg8nU_uxxxjeKSYUrFlCR0tScj-sLfI_2XdyXGtoK8Bhiv5GXAz3IP0GXtZBYBSbd2g30YvOwt1Z8Fe_nYKVIDEqgslBRf4wIRu2Ablnm2ws1_Qil4bRA_zVqU4ou_jwTK8LLYPKgc45WLMKrlKPINj-Ar0ll6LPFcm_X8Hxp_r_kWyUTsSNMCgzNFbzP7CI7865rL0RGduKhqPw=) (Nasdaq:
BCDA), a leader in the development of comprehensive solutions for
cardiovascular regenerative therapies, announces that CEO Dr. Peter Altman
will present at Maxim Group’s Inaugural Emerging Growth Virtual Conference
(https://www.globenewswire.com/Tracker?data=txzEAP6iV_PpmR9sDXK3OYEDelVTZ5bnM-16oZfqaYSLX-rTHhQawDU4_XTfxxEnss0pJ--RbBN9pp7is8NKgbFyts4vzhD5ot5wf7-K1k-c3ds7OVRlPLmCxTTzhtRXNGD5niwhq5OSSpIQjMEuzsG6SBmp1K3brP5gUAxR5xPHPEYZUYafZfqu5axqIVxk)
to be held March 17-19, 2021.

Investors can view Dr. Altman’s live fireside chat presentation at 3:30pm ET
on March 19 and once registered for the conference here,
(https://www.globenewswire.com/Tracker?data=vmPkoE-oR-NBsRPWoT_q4J5NhYfJtEdaGkboc5qz-2pehFOHF4k7Vq5EwcjTtDl_GpmN76CwC-6c5o2iaIE7K0ZwVFzR0xG7zstHai3pV61bQTu5PVNJDFbMVSgnAyya)
can listen to a corporate presentation which will be available on the
conference website. Investors can also request a 1x1 meeting with Dr. Altman
to be arranged following the conclusion of the conference.

About BioCardia

BioCardia
(https://www.globenewswire.com/Tracker?data=Tbg1FkE2HlbyGeidwuDDrgcF3TTCqcPrAl_LOr4yLHLQaCt181H3sND-cqWhwDS4iSPR7vmeth7yAHPsXvLRbA==),
headquartered in San Carlos, California, is developing regenerative biologic
therapies to treat cardiovascular and respiratory disease. CardiAMP autologous
and Neurokinin-1 Receptor Positive allogenic cell therapies are the
Company’s biotherapeutic platforms in clinical development. The Company's
products include the Helix Biotherapeutic Delivery System and its steerable
guide and sheath catheter portfolio. BioCardia also partners with other
biotherapeutic companies to provide its Helix system and clinical support for
their programs studying therapies for the treatment of heart failure, chronic
myocardial ischemia, and acute myocardial infarction. For more information,
visit www.BioCardia.com.

INVESTOR CONTACT:
David McClung, Chief Financial Officer
investors@BioCardia.com
(650) 226-0120

MEDIA CONTACT:
Michelle McAdam, Chronic Communications, Inc.
michelle@chronic-comm.com
(310) 545-6654


(https://www.globenewswire.com/NewsRoom/AttachmentNg/4641bb53-4913-4654-a337-79383a5c7ab9)



GlobeNewswire, Inc. 2021
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.